Report Detail
Global (United States, European Union and China) Fragile X Syndrome Market Research Report 2019-2025
- RnM3334652 |
- 21 April, 2019 |
- Global |
- 110 Pages |
- QYResearch |
- Pharma & Healthcare
In 2019, the market size of Fragile X Syndrome is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Fragile X Syndrome.
This report studies the global market size of Fragile X Syndrome, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Fragile X Syndrome sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Aelis Farma SAS
Alcobra Ltd
AMO Pharma Limited
Confluence Pharmaceuticals LLC
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Marinus Pharmaceuticals, Inc.
MI.TO. Technology S.r.L.
Neuren Pharmaceuticals Limited
Ovid Therapeutics Inc.
Sage Therapeutics, Inc.
Zynerba Pharmaceuticals, Inc.
Market Segment by Product Type
ACT-01
AMO-01
ANAVEX-273
AUT-00206
Bryostatin-1
Cannabidiol
Others
Market Segment by Application
Clinic
Hopital
Research Center
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Fragile X Syndrome status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Fragile X Syndrome manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Fragile X Syndrome are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Fragile X Syndrome Market Size Growth Rate by Type (2019-2025)
- 1.3.2 ACT-01
- 1.3.3 AMO-01
- 1.3.4 ANAVEX-273
- 1.3.5 AUT-00206
- 1.3.6 Bryostatin-1
- 1.3.7 Cannabidiol
- 1.3.8 Others
- 1.4 Market Segment by Application
- 1.4.1 Global Fragile X Syndrome Market Share by Application (2019-2025)
- 1.4.2 Clinic
- 1.4.3 Hopital
- 1.4.4 Research Center
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Fragile X Syndrome Market Size
- 2.1.1 Global Fragile X Syndrome Revenue 2014-2025
- 2.1.2 Global Fragile X Syndrome Sales 2014-2025
- 2.2 Fragile X Syndrome Growth Rate by Regions
- 2.2.1 Global Fragile X Syndrome Sales by Regions 2014-2019
- 2.2.2 Global Fragile X Syndrome Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Fragile X Syndrome Sales by Manufacturers
- 3.1.1 Fragile X Syndrome Sales by Manufacturers 2014-2019
- 3.1.2 Fragile X Syndrome Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Fragile X Syndrome Revenue by Manufacturers (2014-2019)
- 3.2.2 Fragile X Syndrome Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Fragile X Syndrome Market Concentration Ratio (CR5 and HHI)
- 3.3 Fragile X Syndrome Price by Manufacturers
- 3.4 Key Manufacturers Fragile X Syndrome Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Fragile X Syndrome Market
- 3.6 Key Manufacturers Fragile X Syndrome Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 ACT-01 Sales and Revenue (2014-2019)
- 4.1.2 AMO-01 Sales and Revenue (2014-2019)
- 4.1.3 ANAVEX-273 Sales and Revenue (2014-2019)
- 4.1.4 AUT-00206 Sales and Revenue (2014-2019)
- 4.1.5 Bryostatin-1 Sales and Revenue (2014-2019)
- 4.1.6 Cannabidiol Sales and Revenue (2014-2019)
- 4.1.7 Others Sales and Revenue (2014-2019)
- 4.2 Global Fragile X Syndrome Sales Market Share by Type
- 4.3 Global Fragile X Syndrome Revenue Market Share by Type
- 4.4 Fragile X Syndrome Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Fragile X Syndrome Sales by Application
6 United States
- 6.1 United States Fragile X Syndrome Breakdown Data by Company
- 6.2 United States Fragile X Syndrome Breakdown Data by Type
- 6.3 United States Fragile X Syndrome Breakdown Data by Application
7 European Union
- 7.1 European Union Fragile X Syndrome Breakdown Data by Company
- 7.2 European Union Fragile X Syndrome Breakdown Data by Type
- 7.3 European Union Fragile X Syndrome Breakdown Data by Application
8 China
- 8.1 China Fragile X Syndrome Breakdown Data by Company
- 8.2 China Fragile X Syndrome Breakdown Data by Type
- 8.3 China Fragile X Syndrome Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Fragile X Syndrome Breakdown Data by Company
- 9.2 Rest of World Fragile X Syndrome Breakdown Data by Type
- 9.3 Rest of World Fragile X Syndrome Breakdown Data by Application
- 9.4 Rest of World Fragile X Syndrome Breakdown Data by Countries
- 9.4.1 Rest of World Fragile X Syndrome Sales by Countries
- 9.4.2 Rest of World Fragile X Syndrome Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Aelis Farma SAS
- 10.1.1 Aelis Farma SAS Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Fragile X Syndrome
- 10.1.4 Fragile X Syndrome Product Introduction
- 10.1.5 Aelis Farma SAS Recent Development
- 10.2 Alcobra Ltd
- 10.2.1 Alcobra Ltd Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Fragile X Syndrome
- 10.2.4 Fragile X Syndrome Product Introduction
- 10.2.5 Alcobra Ltd Recent Development
- 10.3 AMO Pharma Limited
- 10.3.1 AMO Pharma Limited Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Fragile X Syndrome
- 10.3.4 Fragile X Syndrome Product Introduction
- 10.3.5 AMO Pharma Limited Recent Development
- 10.4 Confluence Pharmaceuticals LLC
- 10.4.1 Confluence Pharmaceuticals LLC Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Fragile X Syndrome
- 10.4.4 Fragile X Syndrome Product Introduction
- 10.4.5 Confluence Pharmaceuticals LLC Recent Development
- 10.5 Eli Lilly and Company
- 10.5.1 Eli Lilly and Company Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Fragile X Syndrome
- 10.5.4 Fragile X Syndrome Product Introduction
- 10.5.5 Eli Lilly and Company Recent Development
- 10.6 F. Hoffmann-La Roche Ltd.
- 10.6.1 F. Hoffmann-La Roche Ltd. Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Fragile X Syndrome
- 10.6.4 Fragile X Syndrome Product Introduction
- 10.6.5 F. Hoffmann-La Roche Ltd. Recent Development
- 10.7 Marinus Pharmaceuticals, Inc.
- 10.7.1 Marinus Pharmaceuticals, Inc. Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Fragile X Syndrome
- 10.7.4 Fragile X Syndrome Product Introduction
- 10.7.5 Marinus Pharmaceuticals, Inc. Recent Development
- 10.8 MI.TO. Technology S.r.L.
- 10.8.1 MI.TO. Technology S.r.L. Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Fragile X Syndrome
- 10.8.4 Fragile X Syndrome Product Introduction
- 10.8.5 MI.TO. Technology S.r.L. Recent Development
- 10.9 Neuren Pharmaceuticals Limited
- 10.9.1 Neuren Pharmaceuticals Limited Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Fragile X Syndrome
- 10.9.4 Fragile X Syndrome Product Introduction
- 10.9.5 Neuren Pharmaceuticals Limited Recent Development
- 10.10 Ovid Therapeutics Inc.
- 10.10.1 Ovid Therapeutics Inc. Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Fragile X Syndrome
- 10.10.4 Fragile X Syndrome Product Introduction
- 10.10.5 Ovid Therapeutics Inc. Recent Development
- 10.11 Sage Therapeutics, Inc.
- 10.12 Zynerba Pharmaceuticals, Inc.
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Fragile X Syndrome Sales Channels
- 11.2.2 Fragile X Syndrome Distributors
- 11.3 Fragile X Syndrome Customers
12 Market Forecast
- 12.1 Global Fragile X Syndrome Sales and Revenue Forecast 2019-2025
- 12.2 Global Fragile X Syndrome Sales Forecast by Type
- 12.3 Global Fragile X Syndrome Sales Forecast by Application
- 12.4 Fragile X Syndrome Forecast by Regions
- 12.4.1 Global Fragile X Syndrome Sales Forecast by Regions 2019-2025
- 12.4.2 Global Fragile X Syndrome Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Fragile X Syndrome. Industry analysis & Market Report on Fragile X Syndrome is a syndicated market report, published as Global (United States, European Union and China) Fragile X Syndrome Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Fragile X Syndrome market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
